BDX - Becton, Dickinson and Company
| Previous Close | 253.46 |
| Open | 252.56 |
| Bid | 252.05 x 1100 |
| Ask | 259.80 x 1000 |
| Day's Range | 252.38 - 258.79 |
| 52 Week Range | 221.47 - 286.72 |
| Volume | 1,867,706 |
| Avg. Volume | 1,518,620 |
| Market Cap | 69.786B |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | 93.14 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.16 (1.25%) |
| Ex-Dividend Date | Mar 08, 2020 |
| 1y Target Est | N/A |
- GlobeNewswire
INVESTOR ALERT: BDX LGND LOPE SBT: Kirby McInerney LLP Continues Investigation of Shareholder Claims
NEW YORK, Feb. 19, 2020 -- The law firm of Kirby McInerney LLP is investigating whether the following publicly-traded companies have violated federal securities laws and/or.
- Business Wire
INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Becton, Dickinson and Company
The law firm of Kirby McInerney LLP is investigating potential claims against Becton, Dickinson and Company ("Becton" or the "Company") (NYSE: BDX). This investigation concerns whether Becton has violated federal securities laws and/or engaged in other unlawful business practices.
- PR Newswire
BD, Babson Diagnostics Announce Strategic Partnership Agreement to Enable Small-Volume Blood Collection for Diagnostic Testing in Retail Settings
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies.
- Business Wire
BECTON, DICKSON AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Becton, Dickson and Company on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against Becton, Dickson and Company (NYSE: BDX) on behalf of Becton stockholders. Our investigation concerns whether Becton has violated the federal securities laws and/or engaged in other unlawful business practices.
- Business Wire
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Becton, Dickinson and Company
The law firm of Kirby McInerney LLP is investigating potential claims against Becton, Dickinson and Company ("Becton" or the "Company") (NYSE: BDX). This investigation concerns whether Becton has violated federal securities laws and/or engaged in other unlawful business practices.
- Business Wire
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Becton, Dickinson and Company Investors (BDX)
The Law Offices of Frank R. Cruz announces an investigation on behalf of Becton, Dickinson and Company ("Becton" or the "Company") (NYSE: BDX) investors concerning the Company and its officers’ possible violations of federal securities laws.
- ACCESSWIRE
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Becton, Dickinson and Company (BDX) on Behalf of Investors
BENSALEM, PA / ACCESSWIRE / February, 6, 2020 / Law Offices of Howard G. Smith announces an investigation on behalf of Becton, Dickinson and Company ("Becton" or the "Company") (NYSE: ...
- PR Newswire
INVESTOR ALERT: Kaplan Fox Investigates Becton, Dickinson And Company
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Becton, Dickinson and Company ("Becton Dickinson" or the "Company") (NYSE: BDX). Investors who purchased Becton Dickinson securities may be affected.
- Business Wire
Glancy Prongay & Murray LLP, a Leading National Securities Fraud Law Firm, Announces Investigation of Becton, Dickinson and Company (BDX) on Behalf of Investors
Glancy Prongay & Murray LLP Announces Investigation of Becton, Dickinson and Company (BDX) on Behalf of Investors
- PR Newswire
BD Board Declares Dividends
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on March 31, 2020 to holders of record on March 10, 2020. The indicated annual dividend rate is $3.16 per share. In addition, the Board of Directors has declared a quarterly dividend of $15.3125 per share on the 6.125% mandatory convertible preferred stock, Series A, payable on May 1, 2020 to holders of record on April 15, 2020. This represents $0.7656 per depositary share (NYSE: BDXA).
- PR Newswire
BD Announces Webcast of Annual Meeting of Shareholders
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 28, 2020, at 1 p.m. (ET).
- PR Newswire
LongueVue Capital Adds Experienced Healthcare Operating Partners to Support New & Existing Investments
LongueVue Capital Partners ("LVC"), a partnership-driven, operator-centric private equity firm based in New Orleans with approximately $500 million of assets under management, announced today that Geoff Glass and Pete Allen have joined the firm as healthcare Operating Partners. Geoff, a seasoned pharma services executive, will focus on the life science space. Pete, a healthcare executive with broad reaching experience, will focus on medical devices and related contract services as well as healthcare supply chain services. The additions of both Pete and Geoff reiterate LVC's commitment to the healthcare industry, which is one of the firm's largest investment verticals.
- PR Newswire
BD to Present at the 38th Annual J.P. Morgan Healthcare Conference
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 6:00 p.m. ET, followed by a question and answer session at 6:30 p.m. ET.
- PR Newswire
BD Launches Enhanced Antimicrobial Stewardship Analytics Capabilities
New antimicrobial stewardship technology will be demonstrated at ASHP 2019 Midyear Meeting FRANKLIN LAKES, N.J. , Nov. 21, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading ...
- PR Newswire
BD Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Investment Corporation
FRANKLIN LAKES, N.J., Nov. 15, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX) announced today that it has been notified of an unsolicited mini-tender offer by TRC Capital Investment Corporation ("TRC") to purchase up to 500,000 shares of BDX common stock at a price of $234.00 per share in cash. TRC's offer price is approximately 4.41 percent below BDX's closing price on November 8, 2019, the last closing price prior to the commencement of the offer. BD is not affiliated with TRC and does not endorse TRC's unsolicited offer.
- PR Newswire
BD to Present at Jefferies 2019 London Healthcare Conference
FRANKLIN LAKES, N.J. , Nov. 14, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Jefferies 2019 ...
- PR Newswire
BD Submits Pre-Market Approval Supplement to FDA for BD Onclarity™ HPV Test with Extended Genotyping Capabilities
FRANKLIN LAKES, N.J. , Nov. 12, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval ...
- PR Newswire
BD Announces Results For 2019 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2020 Guidance
- As reported, full fiscal year revenues of $17.290 billion increased 8.2 percent. - On a comparable, currency-neutral basis, revenues increased 5.1 percent for the full fiscal year. - As reported, full ...
- PR Newswire
BD Announces Live Webcast Of Fourth Fiscal Quarter Earnings Conference Call
FRANKLIN LAKES, N.J. , Oct. 3, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 ...
- PR Newswire
BD Announces Publication of an Independent Analysis of Drug-Coated Balloon Safety Data for Femoropopliteal Peripheral Arterial Disease
Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase FRANKLIN LAKES, N.J. , Sept. 28, 2019 /PRNewswire/ -- BD (Becton, Dickinson ...
- PR Newswire
BD Announces Leadership Succession Plan
FRANKLIN LAKES, N.J., Sept. 26, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020, following the company's annual meeting of shareholders. Forlenza will continue on the BD board of directors, serving as the executive chairman.
- PR Newswire
BD to Present at Investor Healthcare Conferences
FRANKLIN LAKES, N.J. , Aug. 21, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming ...
- PR Newswire
BD Announces Results For 2019 Third Fiscal Quarter; Reaffirms Fiscal 2019 Guidance
- As reported, revenues of $4.350 billion increased 1.7 percent. - On a comparable, currency-neutral basis, revenues increased 5.7 percent. - As reported, diluted earnings per share of $1.51 decreased ...
- PR Newswire
BD releases 2018 Sustainability Report
FRANKLIN LAKES, N.J., July 23, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on management of the environmental, social and governance factors that support the company's 2020 Sustainability Goals. "BD's 2020 sustainability goals reflect our commitment to the role we play in finding solutions to complex global issues in partnership with our employees, customers and stakeholders," said Vincent A. Forlenza, chairman and CEO.
